The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC).
William Nassib William
No relevant relationships to disclose
Vassiliki Papadimitrakopoulou
No relevant relationships to disclose
J. Jack Lee
No relevant relationships to disclose
Li Mao
No relevant relationships to disclose
Heather Lin
No relevant relationships to disclose
Ann M. Gillenwater
No relevant relationships to disclose
Jack W Martin
No relevant relationships to disclose
Ezra E.W. Cohen
No relevant relationships to disclose
Mark W. Lingen
No relevant relationships to disclose
Jay Boyle
No relevant relationships to disclose
Dong Moon Shin
No relevant relationships to disclose
Nadarajah Vigneswaran
No relevant relationships to disclose
Nancy Shinn
No relevant relationships to disclose
Jeffrey Myers
No relevant relationships to disclose
Adel K. El-Naggar
No relevant relationships to disclose
Scott Michael Lippman
No relevant relationships to disclose